
“The quality and coverage of B2B contact database are very impressive...”
Mark J.
`
+3
TiumBio (KOSDAQ: 321550) is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapeutics for patients with rare and incurable diseases. Our mission is to enhance the hope and happiness of humanity through scientific advancements. TiumBio currently has three leading pipeline assets in clinical trials, with TU2218 being investigated in Phase 2 and TU2670 and TU7710 in Phase 1. TU2218 is an oral immuno-oncology therapy targeting TGF-beta and VEGFR2, while TU2670 is an orally active non-peptide GnRH antagonist. Additionally, TU7710 is a bypass-factor treatment specifically designed for hemophilia patients who have developed neutralizing antibodies. TiumBio is located...
Rare diseases,hemophilia,immuno-oncology,discovery,development,small molecules,women's health,and endometiosis
Tiumbio operates in the Biotechnology research industry.
Tiumbio's revenue is 1m - 10m
Tiumbio has 11 - 50 employees.
Get Started with the Free Forever plan! No credit card needed. Enjoy up to 10,000 free email credits per month at no cost.
Start Prospecting from Clodura.AI's database of 600M+ verified B2B contacts and 120M+ direct dials along with 18M+ companies' org charts.
Unlock the prospect's contact details, including verified email, direct dials, add them to cadence, and close more deals.